Background: Improved adherence to inhaled corticosteroids (ICS) is recognized as an important factor in reduced morbidity, mortality and consumption of health care resources. The present study was designed to replicate pervious reports of patient adherence with fluticasone/salmeterol in a single inhaler (FSC), fluticasone and salmeterol in separate inhalers (FP+SAL), fluticasone and montelukast (FP+MON), fluticasone alone (FP) and montelukast alone (MON). Methods: A 24-month observational retrospective study was conducted using administrative claims data. Subjects were X12 years old with 24 months of continuous enrollment; had X1 asthma claim (ICD-9: 493), X1 short-acting beta 2 -agonist claim, and X1 FSC, FP, SAL, or MON claim. Outcomes included asthma medication refill rates and persistence measured by treatment days. This study was designed with a unique population of patients with asthma from different health plans to validate previous findings. Results: A total of 3503 subjects were identified based on their index medication: FSC (996) to the controller regimens of fluticasone and salmeterol in separate inhalers, fluticasone and montelukast, or fluticasone alone and similar to montelukast alone.
Introduction
Inhaled corticosteroids (ICS) have been identified by both the National Asthma Education Prevention Program and the Global Initiative for Asthma (GINA) as the preferred component of controller therapy for patients of all ages and all severity levels of persistent asthma. 1, 2 In addition these guidelines recommend the addition of a long-acting bronchodilator for patients whose asthma is not controlled with an ICS alone. Increased adherence to therapy with ICS is associated with a reduction in emergency department visits, hospitalizations and mortality. [3] [4] [5] [6] Studies show that significant reduction in asthma-related morbidity and mortality are achieved with modest refill persistence of 4-6 canisters of ICS dispensed per year. 5, 6 However, low patient adherence with ICS is common. Refill data indicate that patients treated with ICS have, on average, only 2-4 units of the medication dispensed per year. 7, 8 Poor adherence to ICS is recognized as a contributor to asthma treatment failure resulting in increased morbidity, mortality and increased consumption of health care resources. 9 Furthermore, adherence to pharmaceutical agents in clinical practice may be lower than demonstrated in controlled clinical trials. 10 This study was designed to confirm previous findings that demonstrated increased patient adherence with fluticasone and salmeterol in a single inhaler when compared to the inhaled corticosteroid component of fluticasone and salmeterol in separate inhalers, fluticasone and montelukast combination and with fluticasone monotherapy using administrative claims data. 8 This study employed a unique population of patients with asthma, in different health plans, different regions of the country and included Medicaid patients not previously studied.
Methods

Data source and timeframe
An observational retrospective cohort study was conducted using administrative claims data from three commercial health plans and one Medicaid plan. The commercial health plans with 8 million members and a Medicaid plan that included both Medicaid-managed care and discounted fee-forservice covering more than 1.6 million recipients. The study period included data from April 1, 2000 to September 30, 2002, which allowed for a 24-month study period (12 months pre-index and 12 months post-index), with the index period occurring between April 1 and September 30, 2001.
Cohort definitions
The study participants were divided into the following five cohorts based on the asthma controller medication(s) filled during the index period: 
Study population
Subjects in this analysis were required to have one principal or secondary medical diagnosis claim for asthma (International Classification of Diseases, Ninth Revision [ICD-9]: 493.XX) and at least one short-acting beta 2 -agonist (SABA) prescription claim in the pre-index period. Subjects had one or more pharmacy claim(s) for the medications of interest (FSC, FP, SAL, or MON) during the index period, were 12 years old or older on the index date, and were continuously enrolled during the 24-month study period. Subjects with chronic obstructive lung disease (ICD-9: 491.XX, 492.XX, 494.XX, and 496.XX) or cystic fibrosis (ICD-9: 277.0X) claims during the 24-month study period or claims for any ICS, long-acting beta 2 -agonist (LABA), or leukotriene modifier (LTM) prescriptions during the 12-month pre-index period were excluded. In order to attain comparable cohorts, patients using the highest strengths of FSC (500/ 50 mcg) and FP (220 mcg) were excluded from the analyses. During the 60 days after the index event, ARTICLE IN PRESS subjects could not be dispensed any alternative controller therapy.
Outcomes
The outcomes of interest in the post-index period were (1) asthma medication refill rates and (2) treatment days used as a measure of persistence. Asthma medication refill rates were defined as the number of 1-month (30-day) supply of the medication of interest during the 12-month post-index period. Treatment days for the monotherapy (FSC, FP, and MON) cohorts constituted the total days supply of the medication in the post-index period. Treatment days were calculated for the combination cohorts (FP+SAL and FP+MON) as the total number of days when the FP component of the regimen was supplied. The index prescription for the medication of interest was included in the analyses of refill rates and treatment days. Prescriptions for a 3-month supply were adjusted for this method of dispensing. SABA refill rates in the post-index period were also analyzed for the five cohorts.
Analysis
Descriptive statistics were calculated for each study cohort. Mean and standard deviation or percentage were calculated for continuous and count variables including age, gender, SABA utilization, comorbidities, and percent with a pulmonary function test in the 12-month pre-index period. Chi-square tests were applied for each categorical variable (gender and pulmonary function test) and Wilcoxon rank tests were performed to test the difference between the cohorts for continuous variables (mean age, mean SABA utilization, and mean number of comorbidities).
ANOVA models were used to assess the differences in refill rates and treatment days. For the subjects in the FP+SAL and the FP+MON cohorts, the amount of FP refills and days supply were compared. The models were adjusted for baseline measures, some of which are proxies for severity, including baseline comorbidities, medication use, and hospitalization. All analyses controlled for demographics, health plan, comorbidities, preindex medication use, pre-index asthma ED/hospitalization, and pre-index asthma-related procedures such as nebulizer, injection of asthma-related drugs, pulmonary function test, and allergy skin test. Differences between the cohorts were defined as statistically significant at Po0:05: SAS s Proprietary Software, Release 8.2 was used for all statistical analyses (SAS Institute Inc., Cary, NC).
Results
Subjects
A total of 3503 subjects were identified in the administrative claims data. On the basis of the index medication(s) the patients were classified in one of the following cohorts: FSC (n ¼ 996), FP (n ¼ 1254), FP+SAL (n ¼ 259), FP+MON (n ¼ 101) and MON (n ¼ 893). Baseline demographics are presented in Table 1 . Subjects dispensed FSC were older than those dispensed MON and FP+MON. Mean pre-index SABA use for FSC cohort was significantly higher than for the FP subjects and lower than for MON patients. The FSC cohort had a greater number of comorbidities than those in the MON, 
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Refill rates
The distribution of the mean number of ICS medication fills dispensed in the five cohorts in the post-index period is shown in Fig. 1 
Post-index SABA use
The mean number of SABA prescriptions in the 12-month post-index period for FSC cohort (2.34; 95% CI 2.14-2.55) was significantly lower (Po0:0001) than the number of SABA prescriptions for MON cohort (2.79; 95% CI 2.57-3.01). There were no 
Discussion
This study demonstrates that FSC provides the highest level of adherence to the ICS component of controller therapy and equivalent adherence to montelukast alone. The annual refill rate for FSC was 69-85% higher than the rates for FP, as well as the FP component in FP+SAL, and FP+MON cohorts. In addition, there was no difference in adherence between FSC and montelukast monotherapy. This study in a unique population (different health plans, different regions of the country and inclusion of Medicaid claims) confirms a previous report demonstrating that therapy with fluticasone propionate and salmeterol in a single inhalation device is an effective means of achieving adherence to inhaled corticosteroid therapy for asthma. 8 The consistent findings from the two studies increase the generalizability of the results.
The study has several limitations. It is an observational investigation of administrative medical and pharmacy claims data that were collected for the primary purpose of reimbursement. These data sets do not include information on the clinical status of these patients. In addition, the days' supply of controller medication dispensed is a proxy for medication adherence and does not record actual patient adherence behavior with regards to the medication. There may also be other factors influencing these results such as samples and ' ' borrowed'' medications not included in this analysis that may alter adherence measures. These limitations may overestimate or underestimate the actual use of the medications, but this bias should be expected to occur in each of the cohorts similarly.
Despite advances in therapy, asthma continues to have significant impact on morbidity, mortality and consumption of health care resources. Proper management of asthma and increased adherence to treatment regimen may result in improved longterm asthma control. The literature suggests that simplification of the treatment regimen with fewer medications should achieve better adherence. 11, 12 Perceived improvement and simpler medical regimens may motivate and improve patient adherence. This study confirms the findings of a previous paper 8 types. The findings of these two studies combined with the data from clinical trials demonstrating the superiority of FSC when compared to other controllers adds to the evidence supporting the recommendations of GINA and the NAEPP for controller therapy with ICS+LABA.
